Provided by Tiger Trade Technology Pte. Ltd.

Kymera Therapeutics, Inc.

118.48
+2.151.85%
Post-market: 118.480.00000.00%19:30 EDT
Volume:570.49K
Turnover:68.11M
Market Cap:9.85B
PE:-36.88
High:122.13
Open:119.12
Low:118.27
Close:116.33
52wk High:130.05
52wk Low:47.86
Shares:83.15M
Float Shares:64.87M
Volume Ratio:0.85
T/O Rate:0.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2122
EPS(LYR):-3.6900
ROE:-24.15%
ROA:-15.59%
PB:6.53
PE(LYR):-32.11

Loading ...

Kymera Therapeutics Q1 EPS $(0.71) Beats $(0.88) Estimate, Sales $34.365M Beat $8.614M Estimate

Benzinga Earnings
·
Apr 30

Kymera Q1 revenue jumps on Gilead milestone

Reuters
·
Apr 30

Kymera Q1 net loss widens to $69.2 million; collaboration revenues climb to $34.4 million

Reuters
·
Apr 30

BRIEF-Kymera Therapeutics Q1 EPS USD -0.71

Reuters
·
Apr 30

Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

GlobeNewswire
·
Apr 30

Kymera CEO Nello Mainolfi disposes of common shares worth $2,430,898.39

Reuters
·
Apr 30

Kymera director Bruce Booth disposes of common shares worth $538,687

Reuters
·
Apr 25

Kymera COO Jeremy Chadwick disposes 300 shares for $27,000

Reuters
·
Apr 25

Kymera Therapeutics to report first-quarter financial results, host webcast call

Reuters
·
Apr 23

Kymera COO Jeremy Chadwick disposes of USD 589,510 Kymera Therapeutics shares

Reuters
·
Apr 17

Kymera Therapeutics Chief Business Officer Noah Goodman sells 1,347 shares for $121,230

Reuters
·
Apr 17

Kymera director Bruce Booth disposes of common shares worth $836,290.08

Reuters
·
Apr 17

BUZZ-U.S. STOCKS ON THE MOVE-Conagra, Oracle, Replimune

Reuters
·
Apr 14

BUZZ-U.S. STOCKS ON THE MOVE-Allogene Therapeutics, Adobe, Williams-Sonoma

Reuters
·
Apr 13

FDA grants fast track designation to Kymera Therapeutics KT-621

TIPRANKS
·
Apr 13

Kymera says FDA grants Fast Track designation for KT-621 in eosinophilic asthma

Reuters
·
Apr 13

Kymera Therapeutics Inc - KT-621 Broaden2 Phase 2B Atopic Dermatitis Trial Ongoing, Data Expected by Mid-2027

THOMSON REUTERS
·
Apr 13

Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral Stat6 Degrader for the Treatment of Moderate to Severe Asthma

THOMSON REUTERS
·
Apr 13

Kymera CBO Noah Goodman disposes of common shares worth $893,260.62

Reuters
·
Apr 11

BUZZ-U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-Forman

Reuters
·
Apr 10